RxDoctor Payments Data

Maryruth Nich

Family · Wilmington, DENPI 1063879393

Payments from drug & device makers

$2,014in general payments, 2019–2025

Across 94 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$560
  • Pfizer$389
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$257
  • Amgen$247
  • Kestra Medical Technology Services, Inc.$96
  • Novartis$96
  • plus $370 from 8 others

What the payments were for

  • Food & beverage$2,014100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,014 in reported general payments places this provider in the 75th percentile of 523 family providers in Delaware.

See all family providers in Delaware

Medicare billing

Part B allowed, 2024
$56,031
Medicare patients
479
Services billed
754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban189$257,780
XareltoRivaroxaban49$72,212
JardianceEmpagliflozin29$29,062
Atorvastatin Calcium432$7,399
Ezetimibe129$5,694
Rosuvastatin Calcium182$4,681
Metoprolol Succinate296$4,368
Amlodipine Besylate286$2,704
Hydralazine Hcl118$2,676
Losartan Potassium155$1,761
Carvedilol162$1,676
Lisinopril161$1,382
Valsartan50$1,288
Furosemide198$1,224
Nitroglycerin52$1,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$389$257,780189 claims
Johnson & JohnsonXarelto$54$72,21249 claims
Boehringer IngelheimJardiance$560$29,06229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 523 family providers in Delaware.

Other family in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →